Once-Monthly Long-Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co-occurring Substance Use Disorders: A Multicentre, Observational Study

• Auteurs principaux: Nestor Szerman (Auteur), Ignacio Basurte-Villamor (Auteur), Pablo Vega (Auteur), Jose Martinez-Raga (Auteur), Carlos Parro-Torres (Auteur), Julia Cambra Almerge (Auteur), Lara Grau-López (Auteur), Mario De Matteis (Auteur), Francisco Arias (Auteur)
• Format: Livre
• Publié: Adis, Springer Healthcare, 2020-02-01T00:00:00Z.
• Sujets: article
• Accès en ligne: Connect to this object online.

Abstract Aim To evaluate the efficacy and impact of long-acting injectable (LAI) aripiprazole in patients with schizophrenia with a coexisting substance use disorder (SUD). Patients and methods A multicenter, observational, descriptive and retrospective study was conducted in patients with a DSM-5 d...